Aclarion, Inc. has announced a notable stock purchase by its Chief Financial Officer, Gregory A. Gould. On November 19, 2026, Gould acquired 3,388 shares of the company's common stock at a price of $1.44 per share. This transaction reflects a significant investment in Aclarion, indicating Gould's confidence in the company's future prospects.
Aclarion, Inc. operates in the medical laboratory services sector, classified under SIC 8071. The company trades on the Nasdaq under the ticker symbols ACON and ACONW. Recent filings show that Aclarion is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company.
The filing reveals that following this transaction, Gould now owns a total of 63,388 shares of Aclarion's common stock. This increase in ownership may influence investor sentiment, as insider purchases are often viewed as a positive signal regarding a company's potential for growth.
The recent stock acquisition may affect Aclarion's stakeholders, including current and potential investors, as well as employees who may look to leadership for guidance on the company's direction. Aclarion's focus on the medical laboratory services sector positions it in a competitive landscape where insider confidence can play a crucial role in shaping market perceptions.
The filing does not specify any upcoming events or additional actions following this transaction.
Read Next
Grab Holdings Chief Accounting Officer Sells Shares
Erasca accelerates Phase 3 trial after promising data release
FTAI Aviation director donates 3,000 shares to charity
Granite Construction appoints Stanley G. Bass as director
RenovoRx Director Richard Stark Executes Stock Option
Atmus Filtration Technologies names Interim Chief People Officer









